MOG Antikor İlişkili Hastalıklar
Özet
Miyelin oligodendrosit glikoproteine (MOG) karşı gelişen antikorlarla ilişkili (MOGAD) inflamatuar hastalıklar, santral sinir sisteminde miyelin kılıfını etkileyen klinik sendromlar bütünüdür. Hastalığın seyri yaşa göre değişerek çocuklarda ADEM, daha ileri yaşlarda ise optik nevrit veya transvers miyelit gibi farklı fenotiplerle kendini gösterir. Tanı için ELISA veya Western blot yerine özgüllüğü yüksek olan hücre bazlı analizler altın standarttır. Tedavi süreci, akut ataklar için kortikosteroidler ve plazmaferez gibi yöntemleri, idame için ise immünsüpresif ilaçları kapsar.
Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is an inflammatory central nervous system disorder characterized by immune attacks on myelin-forming oligodendrocytes. Clinical manifestations depend on age, presenting primarily as ADEM in young children and more frequently as optic neuritis or transverse myelitis in older pediatric and adult patients. Accurate diagnosis necessitates cell-based assays rather than standard ELISA or Western blot techniques. Management focuses on acute attacks using corticosteroids or plasma exchange, followed by long-term immunosuppressive therapy to prevent relapses.
Referanslar
Hennes EM, Baumann M, Lechner C, Rostasy K, MOG spectrum disorders and role of MOG-antibodies in clinical practice. Neuropediatrics. Neuropediatrics. 2018 Feb;49(1):3-11.
C.L. de Mol, Y. Wong, E.D. van Pelt, et al. The clinical spectrum and incidence of anti-MOG-associated acquired demyelinating syndromes in children and adults. Mult Scler. 2020 Jun;26(7):806-814.
Reindl M, Di Pauli F, Rostasy K, Berger T. The spectrum of MOG autoantibody-associated demyelinating diseases. Nat Rev Neurol. 2013;9:455–461.
O’Connor KC, McLaughlin KA, De Jager PL, et al. Selfantigen tetramers discriminate between myelin autoantibodies to native or denatured protein. Nat Med 2007;13: 211–217.
Armangue T, Capobianco M, Chalus A, et al. E.U. paediatric MOG consortium consensus: Part 3 - Biomarkers of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders. Eur J Paediatr Neurol . 2020 Nov;29:22-31.
Bruijstens AL, Lechner C, Berliac LF, et al. E.U. paediatric MOG consortium consensus: Part 1 - Classification of clinical phenotypes of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders. Review Eur J Paediatr Neurol. 2020 Nov;29:2-13.
Jurynczyk M, Messina S, Woodhall MR, et al. Clinical Presentation and Prognosis in MOG-Antibody Disease: A UK Study. Brain. 2017;140:3128–3138.
Jarius S, Ruprech K, Kleiter I, et al. MOG-IgG in NMO and Related Disorders: A Multicenter Study of 50 Patients. Part 2: Epidemiology, Clinical Presentation, Radiological and Laboratory Features, Treatment Responses, and Long-Term Outcome. J Neuroinflamm. 2016;13:280.
Y. Hacohen, Y.Y. Wong, C. Lechner, et al. Disease course and treatment responses in children with relapsing myelin oligodendrocyte glycoprotein antibody-associated disease. JAMA Neurol. 2018 Apr 1;75(4):478-487.
Hennes E-M, Baumann M, Schanda K, et al. Prognostic relevance of MOG antibodies in children with an acquired demyelinating syndrome. Neurology. 2017;89:900–8.
Chiriboga AS, Majed M, Fryer J, et al. Association of MOG-IgG serostatus with relapse after acute disseminated encephalomyelitis and proposed diagnostic criteria for MOG-IgG-associated disorders. JAMA Neurol. 2018;75:1355–63.
Hyun J-W, Woodhall MR, Kim S-H, et al. Longitudinal analysis of myelin oligodendrocyte glycoprotein antibodies in CNS inflammatory diseases. J Neurol Neurosurg Psychiatry. 2017;88:811–7.
Baumann M, Sahin K, Lechner C, et al. Clinical and neuroradiological differences of paediatric acute disseminating encephalomyelitis with and without antibodies to the myelin oligodendrocyte glycoprotein. J Neurol Neurosurg Psychiatry. 2015;86:265–72.
Baumann M, Grams A, Djurdjevic T, et al. MRI of the First Event in Pediatric Acquired demyelinating Syndromes with Antibodies to Myelin Oligodendrocyte Glycoprotein. J Neurol. 2018;265:845–855.
Budhram A, Mirian A, Le C, Hosseini-Moghaddam SM, Sharma M, Nicolle MW. Unilateral Cortical FLAIR-Hyperintense Lesions in Anti-MOG-Associated Encephalitis with Seizures (FLAMES): Characterization of a Distinct Clinico-Radiographic Syndrome. J Neurol. 2019;266:2481–2487.
Bartels F, Angelo Lu Angelo, Oertel FC, et al. Clinical and neuroimaging findings in MOGAD-MRI and OCT Review Clin Exp Immunol . Clin Exp Immunol. 2021 Dec;206(3):266-281.
Dubey D, Pittock SJ, Krecke KN, et al. Clinical, radiologic, and prognostic features of myelitis associated with myelin oligodendrocyte glycoprotein autoantibody. JAMA Neurol. 2019;76:301.
Jarius S, Kleiter I, Ruprecht K, et al. MOG-IgG in NMO and Related Disorders: A Multicenter Study of 50 Patients. Part 3: Brainstem Involvement—Frequency, Presentation and Outcome. J Neuroinflamm. 2016;13:281.
Ciccarelli O, Cohen JA, Reingold SC, Weinshenker BG. International Conference on Spinal Cord Involvement and Imaging in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders. Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders. Lancet Neurol. 2019;18:185–97.
Dubey D, Pittock SJ, Krecke KN, et al. Clinical, radiologic, and prognostic features of myelitis associated with myelin oligodendrocyte glycoprotein autoantibody. JAMA Neurol. 2019;76:301.
R.Q. Hintzen, R.C. Dale, R.F. Neuteboom, S. Mar, B. Banwell. Pediatric acquired CNS demyelinating syndromes: features associated with multiple sclerosis. Neurology. 2016 Aug 30;87(9 Suppl 2):S67-73.
Armangue T, Cirera GO, Hernandez EM, et al. Associations of paediatric demyelinating and encephalitic syndromes with myelin oligodendrocyte glycoprotein antibodies: a multicentre observational study Observational Study. Lancet Neurol . 2020 Mar;19(3):234-246.
Ambrosius W, Michalak S, Kozubski W, Kalinowska A. Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: Current Insights into the Disease Pathophysiology, Diagnosis and Management. Int J Mol Sci. 2020 Dec 24;22(1):100.
Jarius S, Paul F, Aktas O, et al. MOG Encephalomyelitis: International Recommendations on Diagnosis and Antibody Testing. J Neuroinflamm. 2018;15:134.
Hoftberger R, Guo Y, Flanagan EP et al. The pathology of central nervous system inflammatory demyelinating disease accompanying myelin oligodendrocyte glycoprotein autoantibody. Acta Neuropathol. 2020; 139: 875–892.
Savransky A, Rubstein A, Rios MH, et al. Prognostic indicators of improvement with therapeutic plasma Exchange in pediatric demyelination. Neurology. 2019 Nov 26;93(22):e2065-e2073.
Bruijstens AL, Wendel EM, Lechner C, et al. E.U. paediatric MOG consortium consensus: Part 5 - Treatment of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders. Eur J Paediatr Neurol . 2020 Nov;29:41-53.
